The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Identifying and managing adverse events of fruquintinib for CRC
Cathy Eng, MD, Vanderbilt-Ingram Cancer Center, Nashville, TN, provides an overview of adverse events reported in the the FRESCO (NCT02314819) and FRESCO-2 (NCT04322539) trials, which assessed fruquintinib in patients with refractory metastatic colorectal cancer (mCRC). In addition to hypertension, which is commonly associated with VEGF inhibitors, asthenia and skin reactions were reported. In both trials, approximately a quarter of patients had a dose reduction, and Dr Eng emphasizes the need to communicate these side effects with patients. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting or Advisory Role – Elevar Therapeutics (Inst); Elevation Oncology; General Electric; GlaxoSmithKline; Gritstone Bio (Inst); Hutchison MediPharma (Inst); Janssen Oncology; Merck (Inst); Merck Serono; natera; Pfizer; Pfizer (Inst); Seagen
